concerns about the enormous responsibilities of dr richard sykes glaxos research and development director and recently appointed chief executive were partly met yesterday when dr goran ando was appointed rd director of glaxo group research the uk research arm and the companys largest research arm analysts had believed that it was impossible for one man to cope as chief executive and be responsible for rd glaxo last year spent nearly pounds 600m on rd more than any other pharmaceutical company it has research sites in the uk us italy france and spain and employs more than 6800 rd specialists dr ando who joined glaxo in 1989 as medical director was made deputy rd director in march last year he was responsible for coordinating all development medical and regulatory functions in the companys international pharmaceutical development programmes he retains responsibility for worldwide drug development a 44yearold swede dr ando was previously at astra the swedish group where he was president of the group research centre before that he held positions at pfizer and bristolmyers dr sykes retains the chairmanship of glaxo group research as well as responsibility for rd on the glaxo board